Edanz is a scientific research support service. We are committed to providing innovative solutions to the challenges faced by the international research community, from individual researcher and clinicians to large institutions.
Edanz helps scientists reach their goals by providing guidance and support at every stage of research planning, execution, writing, and publication processes.
Since our beginnings in 1995 as an English editing company, we have always put our researchers at the center of our business. Learning from their experiences has enabled us to understand the challenges they face; through finding innovative ways to support them in communicating their research globally, we have evolved to become much more than an editing company. We develop tools, such as our Journal Selector and MY Manuscript (tools.edanz.com), that help simplify each stage of the publication process; we produce and manage e-learning platforms such as the Edanz Learning Lab (learning.edanz.com/) and we have delivered educational seminar and workshop programs in over 25 countries.
Our core services of high-quality language and academic editing and publication support combine the skills and expertise of our global network of highly qualified academic editors and research consultants as well as our in-house teams based in Japan and China.
Edanz Pharma (evidence.edanz.com) supports Medical Affairs teams to plan and execute evidence generation strategies: gap and landscape analyses, publication planning, RWE studies, meta analyses, scientific platform development, manuscript development, congress support, and patient engagement strategies.
Our teams include researchers, journal editors, peer reviewers, publication consultants, medical writers, and medical communications specialists.
In 2019 we joined M3 Group (corporate.m3.com); Tokyo Stock Exchange First Section (Securities code 2413).
